Figure 1:
![Figure 1:. Incidence of acute myelogenous leukemia (AML) among myelodysplastic syndrome (MDS) patients treated with or without lenalidomide (Lena) and stratified by lower risk IPSS (low risk or intermediate-1 [0,1]) versus higher risk IPSS (intermediate-2 or high risk [2,3]), Moffitt Cancer Center, 2004-2012](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/124/21/10.1182_blood.v124.21.1912.1912/3/72878fig01.jpeg?Expires=1748142291&Signature=sNwZodSiTmdBUbKJ~FfkPuEmiyurH9J8X1re80~Vg5lM6wx8PqkRYjWYxQRAVljGhX~rNLwmA0kRr6ULI0TdlyKjAPygvTZBEj73eDiDbl0oO~YZAecM6~QusifkoChzdAlMAX259BDRFX6LLQ15HdXOHpRYXorsn7X7lP~uyOVnDxMeLPU45X32dWlXxqY3XYAB4A3xZlmdidvIQiJtMhy0F8PTPx562X48jTxU9HJzJPnECJqc16aV62qhp~rQjajKEP6s7-yuy7Hvbnbot6e-QTvmmmg9ctRKmqcfMYlTiaVPAcGBW9Zy1GMOInSzB0oF814qL6tjn6lJMD3d7w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Incidence of acute myelogenous leukemia (AML) among myelodysplastic syndrome (MDS) patients treated with or without lenalidomide (Lena) and stratified by lower risk IPSS (low risk or intermediate-1 [0,1]) versus higher risk IPSS (intermediate-2 or high risk [2,3]), Moffitt Cancer Center, 2004-2012
